Sharing-our-perspective




Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward


  • FDA requires label changes for opioid analgesics to guide prescribers when gradual tapering is needed

    by
    • Optum Workers' Comp
    | Apr 15, 2019
    Tag Icon
    FDA, Pharmacy, Opioids, opioid analgesics, Clinical
    The U.S. Food and Drug Administration (FDA) issued a safety communication in early April that requires changes to prescribing information for opioid analgesics used in outpatient settings. The goal is to expand the information available to health care providers and patients when opioid analgesics have been prescribed and there is a need to safely decrease the dose or discontinue use of an opioid analgesic


  • New generic options available for Flector® Patch

    by
    | Mar 27, 2019
    Tag Icon
    Generics, Clinical
    Teva Pharmaceuticals has launched an authorized generic version of Flector Patch 1.3% (diclofenac epolamine topical patch), originally manufactured by Pfizer, in the United States (U.S.). Additionally, Greenstone, a Pfizer Company, is also launching an authorized generic version of Flector Patch.


  • PBM 101: A refresher on the role of pharmacy management in workers’ comp

    by
    • Katie Dwyer - Risk & Insurance
    | Mar 12, 2019
    Tag Icon
    Workers' Compensation, workers compensation, Workers Comp, PBM
    Increasingly, PBMs are relying on massive stores of data to identify broader patterns that inform individual prescription decisions. According to David Young, President and CEO of Optum Workers’ Compensation and Auto No-fault, this is a PBM’s true value proposition.


  • FDA advisory committees recommend approval of esketamine nasal spray for treatment-resistant depression

    by
    • Optum for Workers' Compensation
    | Feb 27, 2019
    Tag Icon
    FDA
    Treatment-resistant depression (TRD), is typically defined as failing trials of at least two antidepressant treatments for major depressive disorder. The FDA is expected to make its decision in early March. See potential impact for workers’ comp on our blog.


  • FDA approves first generic of Advair Diskus® inhaler for asthma and COPD

    by
    • Optum for Workers' Compensation
    | Feb 05, 2019
    Tag Icon
    Generics, FDA, FDA approved, Pharmacy, workers compensation, Clinical
    After almost 20 years on the market as a name-brand medication, the FDA has approved the first generic version of Advair Diskus inhaler for asthma and COPD. See availability, timing, dosing and relevance to work comp on our blog.



Stay informed by receiving latest updates

Do you have a question about a blog post?